Seer, Inc.SEEREarnings & Financial Report
Nasdaq · Health Care · Laboratory Analytical Instruments
Seer, Inc. is an American biotechnology company headquartered in Redwood City, California. Established in 2017, the company develops technologies for proteomics research.
Revenue
$3.1M
Gross Profit
$1.7M
Operating Profit
$-27.1M
Net Profit
$-22.9M
Gross Margin
56.3%
Operating Margin
-882.0%
Net Margin
-743.8%
YoY Growth
-23.4%
EPS
$-0.35
Seer, Inc. Q2 FY2024 Financial Summary
Seer, Inc. reported revenue of $3.1M (down 23.4% YoY) for Q2 FY2024, with a net profit of $-22.9M (up 2.5% YoY) (-743.8% margin). Cost of goods sold was $1.3M, operating expenses totaled $28.8M.
Key Financial Metrics
| Total Revenue | $3.1M |
|---|---|
| Net Profit | $-22.9M |
| Gross Margin | 56.3% |
| Operating Margin | -882.0% |
| Report Period | Q2 FY2024 |
Seer, Inc. Annual Revenue by Year
Seer, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $16.6M).
| Year | Annual Revenue |
|---|---|
| 2025 | $16.6M |
| 2024 | $14.2M |
| 2023 | $16.7M |
| 2022 | $15.5M |
Seer, Inc. Quarterly Revenue & Net Profit History
Seer, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $4.2M | +5.0% | $-16.0M | -380.7% |
| Q3 FY2025 | $4.1M | +2.2% | $-18.2M | -442.5% |
| Q2 FY2025 | $4.1M | +31.9% | $-19.4M | -479.5% |
| Q1 FY2025 | $4.2M | +37.1% | $-19.9M | -474.4% |
| Q4 FY2024 | $4.0M | -9.9% | $-21.7M | -543.6% |
| Q3 FY2024 | $4.0M | -3.1% | $-21.3M | -529.0% |
| Q2 FY2024 | $3.1M | -23.4% | $-22.9M | -743.8% |
| Q1 FY2024 | $3.1M | -24.4% | $-20.7M | -674.5% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $3.1M | $3.1M | $4.0M | $4.0M | $4.2M | $4.1M | $4.1M | $4.2M |
| YoY Growth | -24.4% | -23.4% | -3.1% | -9.9% | 37.1% | 31.9% | 2.2% | 5.0% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $422.0M | $406.6M | $383.4M | $366.6M | $347.3M | $322.5M | $308.6M | $296.1M |
| Liabilities | $38.4M | $41.9M | $38.7M | $39.0M | $36.3M | $34.2M | $36.8M | $36.8M |
| Equity | $383.6M | $364.7M | $344.7M | $327.6M | $311.0M | $288.3M | $271.8M | $259.3M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-10.5M | $-10.1M | $-14.1M | $-11.5M | $-11.4M | $-14.7M | $-7.6M | $-10.8M |